Haleon PLC Sponsored ADR (NYSE:HLN) Receives $12.33 Consensus Price Target from Brokerages

Shares of Haleon PLC Sponsored ADR (NYSE:HLN) have been assigned a consensus rating of “Moderate Buy” from the eight analysts that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $12.3250.

Several research firms have recently issued reports on HLN. Morgan Stanley reiterated an “overweight” rating on shares of Haleon in a report on Monday, December 15th. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research report on Thursday, January 22nd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Haleon in a research note on Tuesday, January 20th. HSBC upgraded Haleon from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 21st. Finally, Deutsche Bank Aktiengesellschaft cut Haleon from a “hold” rating to a “sell” rating in a research note on Monday, January 12th.

Institutional Trading of Haleon

A number of large investors have recently added to or reduced their stakes in HLN. IHT Wealth Management LLC lifted its position in shares of Haleon by 6.9% during the 4th quarter. IHT Wealth Management LLC now owns 16,205 shares of the company’s stock valued at $164,000 after acquiring an additional 1,049 shares during the last quarter. National Bank of Canada FI grew its holdings in shares of Haleon by 6.7% in the 3rd quarter. National Bank of Canada FI now owns 17,385 shares of the company’s stock worth $156,000 after acquiring an additional 1,099 shares during the last quarter. Oppenheimer & Co. Inc. grew its holdings in shares of Haleon by 4.7% in the 4th quarter. Oppenheimer & Co. Inc. now owns 24,744 shares of the company’s stock worth $250,000 after acquiring an additional 1,100 shares during the last quarter. Cary Street Partners Financial LLC raised its position in shares of Haleon by 20.1% during the second quarter. Cary Street Partners Financial LLC now owns 6,646 shares of the company’s stock worth $69,000 after purchasing an additional 1,113 shares during the period. Finally, Cardinal Capital Management lifted its holdings in shares of Haleon by 2.4% during the third quarter. Cardinal Capital Management now owns 48,085 shares of the company’s stock valued at $431,000 after purchasing an additional 1,116 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors.

Haleon Stock Up 4.2%

Haleon stock opened at $10.46 on Thursday. Haleon has a 52 week low of $8.71 and a 52 week high of $11.42. The stock has a market cap of $46.57 billion, a price-to-earnings ratio of 26.81 and a beta of 0.18. The company’s 50-day moving average price is $10.51 and its two-hundred day moving average price is $9.86. The company has a current ratio of 0.92, a quick ratio of 0.71 and a debt-to-equity ratio of 0.47.

Haleon Announces Dividend

The firm also recently announced a dividend, which will be paid on Thursday, May 14th. Investors of record on Friday, April 10th will be issued a $0.1307 dividend. This represents a dividend yield of 251.0%. The ex-dividend date is Friday, April 10th. Haleon’s payout ratio is presently 28.21%.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.